GlassScriptPhysician profile
Ellen Belbeck
NPI 1306600945
$4,637.48
in general payments reported to CMS, 2019-2025
24 companies · $3,478 in 2025
The $3,478 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,160 · 2025: $3,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630 · Education: $7.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.90 |
| Education | $7.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.39 | 2024-2025 | |
| Axsome Therapeutics, INC. | $518.74 | 2024-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $459.17 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $413.73 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $318.18 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $294.19 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $288.72 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $288.16 | 2024-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $228.53 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.21 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $174.55 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $166.43 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $155.41 | 2024-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $140.29 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $77.75 | 2024-2025 | Adzenys Xr-Odt, Exxua |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $62.61 | 2025 | Trintellix |
| Lilly USA, LLC | $51.06 | 2025 | Zepbound |
| Corium, LLC | $49.27 | 2024-2025 | Azstarys |
| Tris Pharma INC | $47.70 | 2024-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $42.21 | 2024 | Xelstrym |
| Biogen, INC. | $38.74 | 2025 | Zurzuvae |
| Tempus Ai, INC | $31.66 | 2024 | |
| Novo Nordisk INC | $19.47 | 2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $15.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Belbeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.